Landos Biopharma, Inc.
LABP · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $3 | $3 | $2 |
| G&A Expenses | $6 | $3 | $2 | $2 |
| SG&A Expenses | $6 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $6 | $5 | $4 |
| Operating Income | -$9 | -$6 | -$5 | -$4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | -$1 | $1 |
| Pre-Tax Income | -$9 | -$6 | -$6 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$6 | -$6 | -$4 |
| % Margin | – | – | – | – |
| EPS | -1.43 | -0.99 | -0.94 | -0.63 |
| % Growth | -44.4% | -5.3% | -49.2% | – |
| EPS Diluted | -1.43 | -0.99 | -0.94 | -0.63 |
| Weighted Avg Shares Out | 6 | 6 | 6 | 6 |
| Weighted Avg Shares Out Dil | 6 | 6 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | -$0 | $0 |
| EBITDA | -$9 | -$6 | -$5 | -$4 |
| % Margin | – | – | – | – |